PAQR6 (progestin and adipoQ receptor family member 6) is a plasma membrane progesterone receptor that mediates rapid, non-genomic steroid signaling through G-protein coupled pathways 1. The receptor binds progesterone and other neurosteroids including dehydroepiandrosterone, pregnanolone, pregnenolone, and allopregnanolone, functioning through a Gs-mediated pathway to regulate neurosteroid inhibition of apoptosis 1. PAQR6 plays important roles in nervous system function and has emerged as a significant biomarker in multiple disease contexts. In cancer, PAQR6 upregulation is associated with poor prognosis in prostate cancer, correlating with tumor pathological stages, Gleason scores, and reduced overall survival 2. It also serves as a prognostic biomarker in kidney renal clear cell carcinoma and osteosarcoma, where elevated expression correlates with adverse outcomes 34. In neurological contexts, PAQR6 shows altered expression in Alzheimer's disease middle temporal gyrus and differential isoform usage in prefrontal cortex regions of individuals with adverse childhood experiences 56. Additionally, PAQR6 expression differences are associated with cancer survival disparities across racial groups and vasospasm in subarachnoid hemorrhage patients 78.